ClinicalTrials.Veeva

Menu
I

Instituto Medico Rio Cuarto | Research Center | Rio Cuarto, Argentina

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
TAR-200
Rilematovir
Sotatercept
Vixarelimab
MK-7962-005

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 10 total trials

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) (LIGHTRAY)

Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harde...

Active, not recruiting
Pulmonary Arterial Hypertension
Biological: Sotatercept
Biological: Background PAH Therapy

This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in partici...

Active, not recruiting
PAH
Pulmonary Arterial Hypertension
Biological: Sotatercept

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmo...

Enrolling
Systemic Sclerosis With Lung Involvement
Idiopathic Pulmonary Fibrosis
Drug: Vixarelimab
Drug: Placebo

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatme...

Active, not recruiting
Carcinoma, Squamous Cell, Non-small-cell Lung
Drug: Olaparib
Drug: Paclitaxel

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Active, not recruiting
Bladder Cancer
Biological: Cetrelimab
Drug: TAR-200

This study is a randomized, double-blind, multicenter, placebo-controlled trial to evaluate the safety and efficacy of a novel therapeutic agent, Nov...

Enrolling
Covid19
Biological: Placebo
Biological: Novaferon

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treat...

Active, not recruiting
Carcinoma, Nonsquamous Non-small-cell Lung
Drug: Carboplatin
Drug: Cisplatin

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Acceleron Pharma logo
Janssen (J&J Innovative Medicine) logo
Genentech logo
G
Merck KGaA (EMD Serono) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems